Walleye Capital
GMAB icon

Walleye Capital’s Genmab GMAB Stock Holding History

Walleye Capital’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.2K Buy
+3,100
New +$82.4K ﹤0.01% 3980

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's GMAB Position: Q2 2026 in Review

Walleye Capital reduced its Genmab (GMAB) stake by 93% in Q2 2026, selling an estimated $465K and leaving 1,402 shares worth $38.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4258.

Walleye Capital first reported a position in GMAB in Q1 2025 and has held it in 3 quarters since. The position peaked at $1.39M in Q1 2025. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Walleye Capital held 1,402 shares of Genmab worth $38.5K as of Q2 2026.
  • Walleye Capital sold 17,505 Genmab shares in Q2 2026, an estimated $465K.
  • Genmab made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4258 holding.
  • Walleye Capital first reported a position in Genmab in Q1 2025 and has held it in 3 quarters since.
  • Walleye Capital's Genmab position peaked at $1.39M in Q1 2025.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.